MLTX Stock: Price, Earnings History and SEC Filings
MoonLake Immunotherapeutics (MLTX) last traded at $11.78, down 6.28% on the latest session and up 0.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.84 against an analyst estimate of $-0.90, a beat of 6.7%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
MLTX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 10, 2026 | $-0.84 | $-0.90 | +6.67% |
| Mar 2026 | May 11, 2026 | $-0.98 | $-0.91 | -7.69% |
| Dec 2025 | Feb 25, 2026 | $-0.92 | $-0.92 | +0.00% |
| Sep 2025 | Nov 5, 2025 | $-1.10 | $-0.89 | -23.60% |
MLTX beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How MLTX reacts to earnings
Across its last 8 earnings releases, MLTX moved 3.8% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-10 | Before open | -5.09% |
| 2026-05-11 | Before open | +10.43% |
| 2026-02-23 | Before open | -0.48% |
| 2025-11-05 | Before open | +4.54% |
| 2025-08-05 | Before open | +0.17% |
| 2025-05-12 | After close | -4.08% |
| 2025-02-26 | Before open | +4.03% |
| 2024-11-07 | Before open | -1.57% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
MLTX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$227M | -$196M | – | $-3.53 |
| 2024 | – | -$119M | -$117M | – | $-1.89 |
| 2023 | – | -$36M | -$43M | – | $-0.73 |
| 2022 | – | -$50M | -$56M | – | $-1.70 |
| 2021 | – | -$5M | – | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for MLTX
- 8-K · Sep 30, 2026Other events
- 10-Q · Aug 10, 2026
- 8-K · Aug 10, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jul 15, 2026Other events
- 8-K · Jun 25, 2026Material agreement, Financial statements and exhibits
- 424B5 · Jun 24, 2026
- 424B5 · Jun 22, 2026
- 8-K · Jun 22, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Jun 9, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 8-K · Jun 1, 2026Material agreement
Insider filing activity
MLTX insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
MLTX news
- MoonLake Immunotherapeutics (MLTX) Rides HS Narrative Following Rebound As Undervalued View HoldsOct 25, 2026 · finance.yahoo.com
- MoonLake Immunotherapeutics (MLTX) Stock Trades Above Fair Value On Balance Sheet QuestionsOct 25, 2026 · finance.yahoo.com
- AbbVie Slips Behind Rivals as Lutikizumab Hits 31.4% Response in HS TrialOct 22, 2026 · tikr.com
- MoonLake Soars 18% as Rival AbbVie’s Skin Disease Trial Data “Underwhelms”Oct 22, 2026 · tikr.com
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics (MLTX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in Cayman Islands. Its fiscal year ends in December.